Cidara: European Approval of REZZAYO® (rezafungin) for Invasive Candidiasis

 

• Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.
  
• REZZAYO represents the first new treatment option in over 15 years for patients with invasive candidiasis.
• Cidara is entitled to receive a milestone payment of approximately $11.14 million from Mundipharma for the European Medicines Agency (EMA) approval.

https://www.globenewswire.com/news-release/2023/12/22/2800553/0/en/Cidara-Therapeutics-Announces-European-Approval-of-REZZAYO-rezafungin-for-the-Treatment-of-Invasive-Candidiasis-in-Adults.html